Abstract accepted as E-poster at the European Lung virtual congress 2021 (ELCC)
We are very pleased to announce that our abstract describing our current phase I/II clinical trial objectives and design with our cancer vaccine PDC*lung01 has been accepted for presentation at the European Lung virtual congress 2021 (ELCC) as E-poster with Pr. Jaafar Bennouna a as first author, as specified in the final programme published today online on the ESMO - European Society for Medical Oncology website (186TiP).
Title of the abstract is: An open-label, dose escalation, Phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-Programmed Death-1 (PD-1) treatment in patients with Non-small cell lung cancer (NSCLC).
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information. ESMO’s core mission is to improve the quality of cancer care, from prevention and diagnosis all the way to palliative care and patient follow-up. It is to educate – doctors, cancer patients and the general public – on the best practices and latest advances in oncology. And it is to promote equal access to optimal cancer care for all patients.
About The European Lung Cancer Virtual Congress (ELCC 2021 Virtual)
The European Lung Cancer Virtual Congress (ELCC 2021 Virtual), taking place on 25 – 27 March 2021, is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.
